Paper Details

  1. Home
  2. Paper Details

Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.

Author: AmrheinJennifer A, BeyettTyler S, EckMichael J, FengWilliam W, HankeThomas, JännePasi A, KnappStefan, KrämerAndreas, RanaJaimin K, SchaeffnerIlse K, WeckesserJanik

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study describes the development of a new EGFR inhibitor with improved selectivity for EGFR mutations. Activating mutations in the epidermal growth factor receptor (EGFR) are common drivers of non-small-cell lung cancer (NSCLC). EGFR inhibitors like gefitinib and erlotinib are effective but have off-target effects and can inhibit wild-type EGFR, leading to side effects. This study utilizes a macrocyclic strategy to enhance selectivity for EGFR mutations, potentially improving treatment efficacy while minimizing side effects.
Paper Details　
Original Abstract of the Article :
Activating mutations in the epidermal growth factor receptor (EGFR) are frequent oncogenic drivers of non-small-cell lung cancer (NSCLC). The most frequent alterations in EGFR are short in-frame deletions in exon 19 (Del19) and the missense mutation L858R, which both lead to increased activity and s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/36384036

データ提供：米国国立医学図書館（NLM）

EGFR Inhibitors: A Quest for Specificity in the Cancerous Desert

This research takes us on a thrilling quest through the vast and complex landscape of cancer research. The goal is to develop more targeted therapies that effectively fight cancer without harming healthy cells. This study focuses on EGFR inhibitors, which are like weapons that target a specific type of cancer cell, which is like a rogue oasis in the desert of the body. The researchers are working to improve the specificity of these inhibitors, ensuring they hit their target with precision, like a skilled archer taking aim at the heart of the oasis.

Macrocyclization: A Precise Targeting System

The study explored a new approach called macrocyclization, which essentially involves adding a ring structure to the inhibitor molecule, which is like building a more precise targeting system for the oasis. This modification significantly improved the selectivity of the inhibitor, allowing it to target the mutated EGFR, which is like the oasis's hidden spring, without affecting the normal EGFR, which is like the surrounding desert. The inhibitor showed strong potency against the mutated EGFR, effectively shutting down the oasis without impacting the surrounding ecosystem.

Precision Targeting in the War Against Cancer

This research is a promising step towards developing more effective and safer cancer treatments. It's like developing a new weapon that can eliminate the oasis without causing any collateral damage. By improving the specificity of EGFR inhibitors, we can potentially minimize side effects and improve the lives of cancer patients.

Dr.Camel's Conclusion

This study exemplifies the transformative potential of precise targeting in cancer therapy. It's like a desert explorer discovering a new, more efficient route to a hidden oasis. The research team's innovative approach has yielded a promising new drug candidate with increased selectivity, a crucial step towards developing more effective and safer therapies for EGFR-driven cancers.

Date :
  1. Date Completed 2022-12-15
  2. Date Revised 2023-12-12
Further Info :

Pubmed ID

36384036

DOI: Digital Object Identifier

NIHMS1914825

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.